Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 21 | 2023 | 5442 | 0.920 |
Why?
|
Yttrium Radioisotopes | 5 | 2015 | 93 | 0.900 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 5 | 2023 | 1378 | 0.880 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 11 | 2015 | 693 | 0.810 |
Why?
|
Hodgkin Disease | 8 | 2022 | 1415 | 0.760 |
Why?
|
Lymphoma, B-Cell | 8 | 2021 | 931 | 0.590 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2021 | 11524 | 0.540 |
Why?
|
Transplantation, Autologous | 14 | 2023 | 2124 | 0.480 |
Why?
|
Data Mining | 1 | 2019 | 537 | 0.480 |
Why?
|
Antibodies, Monoclonal | 11 | 2015 | 9274 | 0.450 |
Why?
|
Therapeutics | 1 | 2013 | 116 | 0.430 |
Why?
|
Guillain-Barre Syndrome | 1 | 2014 | 120 | 0.430 |
Why?
|
Remission Induction | 12 | 2016 | 2386 | 0.400 |
Why?
|
Graft vs Host Disease | 7 | 2023 | 2957 | 0.370 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2019 | 1596 | 0.370 |
Why?
|
Dendritic Cells | 9 | 2014 | 2725 | 0.350 |
Why?
|
Cancer Vaccines | 6 | 2016 | 1023 | 0.340 |
Why?
|
Antineoplastic Agents | 13 | 2022 | 13695 | 0.340 |
Why?
|
Lymphoma, Primary Effusion | 1 | 2008 | 17 | 0.330 |
Why?
|
Lymphoma, Non-Hodgkin | 5 | 2017 | 1381 | 0.320 |
Why?
|
Multiple Myeloma | 8 | 2013 | 5181 | 0.320 |
Why?
|
Hematopoietic Stem Cell Mobilization | 4 | 2017 | 227 | 0.320 |
Why?
|
Radioimmunotherapy | 4 | 2015 | 91 | 0.310 |
Why?
|
Information Storage and Retrieval | 1 | 2013 | 824 | 0.300 |
Why?
|
Mucin-1 | 4 | 2017 | 543 | 0.300 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2012 | 648 | 0.290 |
Why?
|
Extravasation of Diagnostic and Therapeutic Materials | 1 | 2006 | 105 | 0.260 |
Why?
|
Lymphoma, Mantle-Cell | 2 | 2020 | 233 | 0.260 |
Why?
|
Anilides | 2 | 2017 | 408 | 0.250 |
Why?
|
Electronic Health Records | 2 | 2019 | 4468 | 0.250 |
Why?
|
Leukemia, Myeloid, Acute | 6 | 2017 | 3523 | 0.240 |
Why?
|
Salvage Therapy | 3 | 2021 | 1275 | 0.230 |
Why?
|
Doxorubicin | 6 | 2021 | 2234 | 0.210 |
Why?
|
Nitrogen Mustard Compounds | 2 | 2014 | 45 | 0.210 |
Why?
|
Stem Cell Transplantation | 5 | 2023 | 1620 | 0.200 |
Why?
|
Antibodies, Bispecific | 1 | 2022 | 164 | 0.180 |
Why?
|
Lymphoma, Follicular | 3 | 2022 | 435 | 0.180 |
Why?
|
Etoposide | 4 | 2021 | 641 | 0.160 |
Why?
|
Radiation Injuries | 1 | 2006 | 1180 | 0.160 |
Why?
|
Disease-Free Survival | 10 | 2019 | 6895 | 0.160 |
Why?
|
Health Records, Personal | 1 | 2019 | 124 | 0.160 |
Why?
|
Databases, Factual | 1 | 2013 | 7729 | 0.150 |
Why?
|
Vinblastine | 1 | 2019 | 502 | 0.150 |
Why?
|
Leukocytes, Mononuclear | 4 | 2023 | 1836 | 0.150 |
Why?
|
Quinazolinones | 1 | 2019 | 221 | 0.150 |
Why?
|
Antigens, CD | 3 | 2014 | 4026 | 0.140 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 2 | 2012 | 272 | 0.140 |
Why?
|
T-Lymphocytes | 5 | 2018 | 10180 | 0.140 |
Why?
|
Skin Diseases, Parasitic | 1 | 2016 | 13 | 0.140 |
Why?
|
Dacarbazine | 1 | 2019 | 566 | 0.140 |
Why?
|
Amebiasis | 1 | 2016 | 34 | 0.140 |
Why?
|
Purines | 1 | 2019 | 594 | 0.130 |
Why?
|
Aged | 32 | 2021 | 163280 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2023 | 9239 | 0.130 |
Why?
|
Boronic Acids | 3 | 2010 | 965 | 0.130 |
Why?
|
Phenotype | 1 | 2013 | 16365 | 0.130 |
Why?
|
Ifosfamide | 3 | 2013 | 228 | 0.130 |
Why?
|
Rifamycins | 1 | 2014 | 25 | 0.130 |
Why?
|
Survival Rate | 9 | 2021 | 12788 | 0.130 |
Why?
|
Humans | 69 | 2023 | 744343 | 0.120 |
Why?
|
Cell Proliferation | 6 | 2017 | 10481 | 0.120 |
Why?
|
Graft vs Leukemia Effect | 1 | 2014 | 111 | 0.120 |
Why?
|
Miller Fisher Syndrome | 1 | 2014 | 7 | 0.120 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2017 | 491 | 0.120 |
Why?
|
Pyrazines | 3 | 2010 | 1230 | 0.120 |
Why?
|
Cyclophosphamide | 3 | 2021 | 2242 | 0.120 |
Why?
|
Middle Aged | 39 | 2021 | 213383 | 0.120 |
Why?
|
Stiff-Person Syndrome | 1 | 2013 | 28 | 0.110 |
Why?
|
Lymphocyte Transfusion | 1 | 2014 | 236 | 0.110 |
Why?
|
Plasmapheresis | 1 | 2014 | 211 | 0.110 |
Why?
|
Gangliosides | 1 | 2014 | 137 | 0.110 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 207 | 0.110 |
Why?
|
Documentation | 1 | 2019 | 871 | 0.110 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2017 | 627 | 0.110 |
Why?
|
Opportunistic Infections | 1 | 2016 | 389 | 0.110 |
Why?
|
Herpesvirus 3, Human | 1 | 2014 | 204 | 0.110 |
Why?
|
Antigens, CD1 | 2 | 2008 | 437 | 0.110 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2014 | 2016 | 0.110 |
Why?
|
Immunologic Factors | 2 | 2013 | 1580 | 0.110 |
Why?
|
Methylprednisolone | 1 | 2014 | 387 | 0.100 |
Why?
|
Neoplasm, Residual | 3 | 2023 | 973 | 0.100 |
Why?
|
Cluster Analysis | 1 | 2019 | 2715 | 0.100 |
Why?
|
Mitoxantrone | 2 | 2003 | 152 | 0.100 |
Why?
|
Peptides | 2 | 2015 | 4409 | 0.100 |
Why?
|
Sulfonamides | 1 | 2021 | 1938 | 0.100 |
Why?
|
Virus Activation | 1 | 2014 | 319 | 0.100 |
Why?
|
Positron-Emission Tomography | 4 | 2015 | 6234 | 0.100 |
Why?
|
Heterocyclic Compounds | 1 | 2012 | 249 | 0.100 |
Why?
|
Transplantation Conditioning | 1 | 2018 | 1598 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2021 | 5172 | 0.100 |
Why?
|
Herpes Zoster | 1 | 2014 | 264 | 0.100 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2016 | 546 | 0.100 |
Why?
|
Male | 36 | 2021 | 350118 | 0.090 |
Why?
|
Cytarabine | 3 | 2020 | 692 | 0.090 |
Why?
|
Leukapheresis | 3 | 2014 | 131 | 0.090 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2015 | 1157 | 0.090 |
Why?
|
Thalidomide | 2 | 2012 | 890 | 0.090 |
Why?
|
Transplantation, Homologous | 4 | 2021 | 4776 | 0.090 |
Why?
|
Antigens, Neoplasm | 2 | 2016 | 1988 | 0.090 |
Why?
|
Immunity, Cellular | 2 | 2013 | 1607 | 0.090 |
Why?
|
Autoantigens | 1 | 2014 | 892 | 0.090 |
Why?
|
Consciousness Disorders | 1 | 2014 | 418 | 0.090 |
Why?
|
Adult | 33 | 2021 | 214055 | 0.090 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2014 | 652 | 0.090 |
Why?
|
Androgen Antagonists | 1 | 1998 | 1377 | 0.080 |
Why?
|
Granzymes | 1 | 2010 | 271 | 0.080 |
Why?
|
Hematopoietic Stem Cells | 2 | 2012 | 3386 | 0.080 |
Why?
|
Vidarabine | 1 | 2009 | 345 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1671 | 0.080 |
Why?
|
International Classification of Diseases | 1 | 2013 | 867 | 0.080 |
Why?
|
Skin Neoplasms | 2 | 2018 | 5686 | 0.080 |
Why?
|
Immunophenotyping | 6 | 2013 | 1880 | 0.070 |
Why?
|
Female | 39 | 2021 | 380194 | 0.070 |
Why?
|
Maximum Tolerated Dose | 2 | 2021 | 892 | 0.070 |
Why?
|
Pancreas | 1 | 2014 | 1686 | 0.070 |
Why?
|
Vaccination | 2 | 2016 | 3278 | 0.070 |
Why?
|
Herpesviridae Infections | 1 | 2008 | 277 | 0.070 |
Why?
|
Thrombocytopenia | 1 | 2015 | 1179 | 0.070 |
Why?
|
Antigens, Differentiation | 1 | 2010 | 927 | 0.070 |
Why?
|
Herpesvirus 8, Human | 1 | 2008 | 258 | 0.070 |
Why?
|
Combined Modality Therapy | 4 | 2014 | 8642 | 0.070 |
Why?
|
Radiopharmaceuticals | 2 | 2014 | 2645 | 0.070 |
Why?
|
Dyspnea | 1 | 2014 | 1303 | 0.070 |
Why?
|
Follow-Up Studies | 9 | 2021 | 39050 | 0.070 |
Why?
|
Cerebellum | 1 | 2013 | 1488 | 0.070 |
Why?
|
Cell Fusion | 3 | 2011 | 297 | 0.070 |
Why?
|
Antigens, CD34 | 2 | 2013 | 657 | 0.070 |
Why?
|
Chronic Disease | 5 | 2023 | 9146 | 0.070 |
Why?
|
Glycoproteins | 1 | 2014 | 2263 | 0.070 |
Why?
|
Pyridines | 1 | 2017 | 2825 | 0.070 |
Why?
|
Autoantibodies | 1 | 2014 | 2035 | 0.060 |
Why?
|
Intestines | 1 | 2014 | 1924 | 0.060 |
Why?
|
Neoplastic Stem Cells | 1 | 2013 | 1376 | 0.060 |
Why?
|
Prednisone | 2 | 2021 | 1574 | 0.060 |
Why?
|
Aged, 80 and over | 9 | 2019 | 57776 | 0.060 |
Why?
|
Liposomes | 1 | 2008 | 759 | 0.060 |
Why?
|
Treatment Outcome | 16 | 2021 | 63114 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4149 | 0.060 |
Why?
|
Software | 1 | 2019 | 4443 | 0.060 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2016 | 2988 | 0.060 |
Why?
|
Interleukin-2 | 1 | 2011 | 1904 | 0.060 |
Why?
|
Hematologic Neoplasms | 2 | 2014 | 1832 | 0.060 |
Why?
|
Survival Analysis | 5 | 2019 | 10252 | 0.060 |
Why?
|
Pilot Projects | 2 | 2013 | 8324 | 0.060 |
Why?
|
Lung Diseases | 1 | 2014 | 1886 | 0.060 |
Why?
|
Intestinal Mucosa | 1 | 2014 | 3036 | 0.060 |
Why?
|
Antigens, CD19 | 2 | 2022 | 380 | 0.050 |
Why?
|
Th1 Cells | 1 | 2008 | 1057 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 4034 | 0.050 |
Why?
|
Killer Cells, Natural | 3 | 2008 | 2133 | 0.050 |
Why?
|
Acute Kidney Injury | 1 | 2014 | 1972 | 0.050 |
Why?
|
Immunotherapy | 3 | 2013 | 4445 | 0.050 |
Why?
|
Apoptosis | 2 | 2015 | 9727 | 0.050 |
Why?
|
Filgrastim | 1 | 2001 | 133 | 0.050 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2008 | 903 | 0.050 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 2 | 2016 | 180 | 0.050 |
Why?
|
Pneumococcal Vaccines | 1 | 2005 | 391 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 5535 | 0.050 |
Why?
|
HIV | 1 | 2008 | 1604 | 0.050 |
Why?
|
Immunoenzyme Techniques | 2 | 2015 | 1799 | 0.050 |
Why?
|
Viral Vaccines | 1 | 2006 | 636 | 0.050 |
Why?
|
Internet | 1 | 2013 | 3064 | 0.050 |
Why?
|
Bone Marrow Transplantation | 2 | 1998 | 2765 | 0.050 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11031 | 0.050 |
Why?
|
Breast Neoplasms | 7 | 2002 | 20822 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 3 | 2015 | 20129 | 0.050 |
Why?
|
Antibody Formation | 1 | 2005 | 1402 | 0.050 |
Why?
|
Lymphoma | 1 | 2009 | 1877 | 0.040 |
Why?
|
Mice, Inbred NOD | 2 | 2015 | 1878 | 0.040 |
Why?
|
Vincristine | 1 | 2021 | 1039 | 0.040 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2019 | 38 | 0.040 |
Why?
|
Mice, SCID | 2 | 2015 | 2716 | 0.040 |
Why?
|
Algorithms | 1 | 2019 | 13881 | 0.040 |
Why?
|
Recurrence | 5 | 2014 | 8340 | 0.040 |
Why?
|
Flow Cytometry | 3 | 2015 | 5974 | 0.040 |
Why?
|
Clinical Trials as Topic | 4 | 2017 | 7913 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2001 | 588 | 0.040 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2020 | 339 | 0.040 |
Why?
|
Ondansetron | 1 | 1998 | 90 | 0.040 |
Why?
|
Transplantation Immunology | 1 | 2000 | 546 | 0.040 |
Why?
|
Lymphocyte Activation | 4 | 2012 | 5524 | 0.040 |
Why?
|
Steroids | 1 | 2023 | 930 | 0.040 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2007 | 1052 | 0.040 |
Why?
|
Enoxaparin | 1 | 2020 | 377 | 0.040 |
Why?
|
Tosyl Compounds | 1 | 1998 | 113 | 0.040 |
Why?
|
Flutamide | 1 | 1998 | 96 | 0.040 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 1998 | 281 | 0.040 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 1998 | 131 | 0.040 |
Why?
|
Antiemetics | 1 | 1998 | 177 | 0.040 |
Why?
|
Anti-HIV Agents | 1 | 2012 | 4256 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2003 | 2971 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 4751 | 0.040 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2011 | 1369 | 0.040 |
Why?
|
Drug Administration Schedule | 4 | 2012 | 4933 | 0.040 |
Why?
|
Th2 Cells | 1 | 2001 | 1061 | 0.040 |
Why?
|
Acanthamoeba castellanii | 1 | 2016 | 10 | 0.040 |
Why?
|
Blotting, Western | 2 | 2015 | 5179 | 0.040 |
Why?
|
Lymph Nodes | 2 | 2006 | 3474 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2014 | 7181 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2018 | 15295 | 0.030 |
Why?
|
Vitamin D | 1 | 2010 | 3223 | 0.030 |
Why?
|
Glucocorticoids | 2 | 2018 | 2107 | 0.030 |
Why?
|
Melphalan | 3 | 2002 | 431 | 0.030 |
Why?
|
Carboplatin | 2 | 2013 | 801 | 0.030 |
Why?
|
Vomiting | 1 | 1998 | 636 | 0.030 |
Why?
|
Interleukin-4 | 2 | 2014 | 1147 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 1998 | 11124 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2008 | 11366 | 0.030 |
Why?
|
Antigens, CD1d | 2 | 2008 | 220 | 0.030 |
Why?
|
Dexamethasone | 2 | 2013 | 1951 | 0.030 |
Why?
|
NADP | 1 | 2015 | 226 | 0.030 |
Why?
|
Fatigue | 2 | 2012 | 1531 | 0.030 |
Why?
|
Cecum | 1 | 2014 | 237 | 0.030 |
Why?
|
Young Adult | 5 | 2021 | 56430 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2001 | 2513 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2022 | 1270 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2021 | 4479 | 0.030 |
Why?
|
Prognosis | 4 | 2022 | 29063 | 0.030 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2015 | 431 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2540 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2017 | 1341 | 0.030 |
Why?
|
Mutation | 1 | 2017 | 29786 | 0.030 |
Why?
|
Glutathione | 1 | 2015 | 589 | 0.030 |
Why?
|
Nitriles | 1 | 1998 | 956 | 0.030 |
Why?
|
Histocompatibility Testing | 1 | 2014 | 741 | 0.030 |
Why?
|
Treatment Failure | 2 | 2013 | 2618 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2017 | 1677 | 0.030 |
Why?
|
Metalloendopeptidases | 1 | 1993 | 396 | 0.030 |
Why?
|
Benzylamines | 1 | 2012 | 223 | 0.030 |
Why?
|
Blood Component Removal | 1 | 2012 | 125 | 0.030 |
Why?
|
Th1-Th2 Balance | 1 | 2011 | 38 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2001 | 6622 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2017 | 987 | 0.020 |
Why?
|
Immunization | 2 | 2006 | 1256 | 0.020 |
Why?
|
Immune System | 1 | 2016 | 805 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 21683 | 0.020 |
Why?
|
Time Factors | 5 | 2017 | 40075 | 0.020 |
Why?
|
Thorax | 1 | 2014 | 547 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2016 | 1850 | 0.020 |
Why?
|
Necrosis | 1 | 2015 | 1643 | 0.020 |
Why?
|
Lymphocyte Culture Test, Mixed | 2 | 2001 | 517 | 0.020 |
Why?
|
RNA, Messenger | 3 | 2015 | 13033 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2016 | 847 | 0.020 |
Why?
|
Retrospective Studies | 4 | 2021 | 77449 | 0.020 |
Why?
|
Cells, Cultured | 4 | 2014 | 19229 | 0.020 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2010 | 71 | 0.020 |
Why?
|
Carcinoma | 1 | 2002 | 2375 | 0.020 |
Why?
|
Observation | 1 | 2011 | 312 | 0.020 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2011 | 349 | 0.020 |
Why?
|
Paclitaxel | 3 | 2002 | 1708 | 0.020 |
Why?
|
Drug Interactions | 1 | 2014 | 1460 | 0.020 |
Why?
|
Cohort Studies | 4 | 2018 | 40561 | 0.020 |
Why?
|
Mitogens | 1 | 2010 | 232 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 2 | 2012 | 1838 | 0.020 |
Why?
|
Cell Communication | 1 | 2017 | 1621 | 0.020 |
Why?
|
Antibodies, Protozoan | 1 | 2010 | 253 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1998 | 1524 | 0.020 |
Why?
|
Atrophy | 1 | 2014 | 1583 | 0.020 |
Why?
|
Axilla | 2 | 2006 | 595 | 0.020 |
Why?
|
Sensation Disorders | 1 | 2010 | 155 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1061 | 0.020 |
Why?
|
Immunoblotting | 1 | 2012 | 1682 | 0.020 |
Why?
|
Antigens, Protozoan | 1 | 2010 | 322 | 0.020 |
Why?
|
Retreatment | 1 | 2010 | 610 | 0.020 |
Why?
|
Acute Disease | 1 | 2018 | 7149 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 1998 | 2494 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2011 | 1588 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2014 | 1265 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2015 | 2077 | 0.020 |
Why?
|
Neutropenia | 1 | 2012 | 895 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2015 | 6314 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2015 | 3557 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2013 | 2649 | 0.020 |
Why?
|
Myelodysplastic Syndromes | 1 | 2017 | 1352 | 0.020 |
Why?
|
Cisplatin | 1 | 2013 | 1662 | 0.020 |
Why?
|
Cell Polarity | 1 | 2010 | 645 | 0.020 |
Why?
|
Lymphocytes | 1 | 2014 | 2617 | 0.020 |
Why?
|
Colon | 1 | 2014 | 1772 | 0.020 |
Why?
|
Clone Cells | 1 | 2010 | 1692 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2010 | 498 | 0.020 |
Why?
|
Disease Progression | 3 | 2011 | 13284 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2014 | 12959 | 0.020 |
Why?
|
Drug Resistance | 1 | 2011 | 1609 | 0.020 |
Why?
|
Lymphoproliferative Disorders | 1 | 2009 | 523 | 0.020 |
Why?
|
Sirolimus | 1 | 2012 | 1564 | 0.020 |
Why?
|
Renal Dialysis | 1 | 2014 | 1786 | 0.020 |
Why?
|
Animals | 4 | 2017 | 168757 | 0.020 |
Why?
|
Tissue Donors | 1 | 2014 | 2240 | 0.020 |
Why?
|
Anticoagulants | 1 | 2020 | 4599 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2011 | 10943 | 0.020 |
Why?
|
Administration, Oral | 1 | 2012 | 3913 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2915 | 0.020 |
Why?
|
Forkhead Transcription Factors | 1 | 2011 | 1613 | 0.020 |
Why?
|
Antigen Presentation | 1 | 2010 | 1284 | 0.010 |
Why?
|
False Positive Reactions | 1 | 2006 | 981 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2015 | 3086 | 0.010 |
Why?
|
Mice | 3 | 2017 | 81183 | 0.010 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2011 | 1821 | 0.010 |
Why?
|
Antigens, CD20 | 1 | 2004 | 199 | 0.010 |
Why?
|
Lymphatic Metastasis | 2 | 2006 | 2924 | 0.010 |
Why?
|
Subtraction Technique | 1 | 2006 | 525 | 0.010 |
Why?
|
Vaccines, Conjugate | 1 | 2005 | 333 | 0.010 |
Why?
|
Anemia | 1 | 2012 | 1506 | 0.010 |
Why?
|
Neoplasm Metastasis | 3 | 2002 | 4851 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 2004 | 898 | 0.010 |
Why?
|
Adolescent | 3 | 2021 | 85781 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4420 | 0.010 |
Why?
|
Pain | 2 | 2010 | 4986 | 0.010 |
Why?
|
Thiotepa | 1 | 2002 | 66 | 0.010 |
Why?
|
Immunoglobulin M | 1 | 2007 | 1537 | 0.010 |
Why?
|
Biopsy | 1 | 2014 | 6756 | 0.010 |
Why?
|
Cell Separation | 1 | 2008 | 1751 | 0.010 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2001 | 82 | 0.010 |
Why?
|
Life Tables | 1 | 2002 | 370 | 0.010 |
Why?
|
Age Factors | 1 | 2018 | 18370 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2010 | 3206 | 0.010 |
Why?
|
MicroRNAs | 1 | 2017 | 3752 | 0.010 |
Why?
|
Phytohemagglutinins | 1 | 2000 | 170 | 0.010 |
Why?
|
CD4-CD8 Ratio | 1 | 2000 | 112 | 0.010 |
Why?
|
Gene Expression | 1 | 1993 | 7799 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 16689 | 0.010 |
Why?
|
Pneumococcal Infections | 1 | 2005 | 497 | 0.010 |
Why?
|
Prospective Studies | 3 | 2014 | 53288 | 0.010 |
Why?
|
Signal Transduction | 2 | 2015 | 23403 | 0.010 |
Why?
|
Hypersensitivity, Delayed | 1 | 2000 | 484 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2006 | 1257 | 0.010 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2002 | 415 | 0.010 |
Why?
|
Antibodies, Bacterial | 1 | 2005 | 1470 | 0.010 |
Why?
|
Skin Tests | 1 | 2000 | 613 | 0.010 |
Why?
|
United States | 2 | 2018 | 69872 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 2002 | 2031 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2010 | 4386 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 8949 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2015 | 21746 | 0.010 |
Why?
|
Progesterone | 1 | 2002 | 776 | 0.010 |
Why?
|
Antigens, Surface | 1 | 2001 | 1663 | 0.010 |
Why?
|
Fluorouracil | 1 | 2002 | 1619 | 0.010 |
Why?
|
Immunoglobulins | 1 | 2000 | 881 | 0.010 |
Why?
|
Bone Marrow | 1 | 2007 | 2948 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2013 | 11483 | 0.010 |
Why?
|
HeLa Cells | 1 | 2001 | 3128 | 0.010 |
Why?
|
Methotrexate | 1 | 2002 | 1727 | 0.010 |
Why?
|
Estrogens | 1 | 2002 | 1566 | 0.010 |
Why?
|
Matrix Metalloproteinase 11 | 1 | 1993 | 14 | 0.010 |
Why?
|
Immunity | 1 | 2000 | 1012 | 0.010 |
Why?
|
Cathepsin D | 1 | 1993 | 61 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2002 | 2942 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1993 | 1581 | 0.010 |
Why?
|
Risk Factors | 1 | 2018 | 72290 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2002 | 12245 | 0.000 |
Why?
|
Carcinoma in Situ | 1 | 1993 | 806 | 0.000 |
Why?
|
Cell Line | 1 | 2001 | 15997 | 0.000 |
Why?
|
Proportional Hazards Models | 1 | 2002 | 12354 | 0.000 |
Why?
|
Cytokines | 1 | 2001 | 7322 | 0.000 |
Why?
|
Melanoma | 1 | 1985 | 5510 | 0.000 |
Why?
|
Liver | 1 | 2002 | 7474 | 0.000 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 1993 | 1101 | 0.000 |
Why?
|
Receptors, Estrogen | 1 | 1993 | 2187 | 0.000 |
Why?
|
Culture Techniques | 1 | 1985 | 554 | 0.000 |
Why?
|
Child, Preschool | 1 | 2005 | 41006 | 0.000 |
Why?
|
Mitosis | 1 | 1985 | 1208 | 0.000 |
Why?
|
Cell Division | 1 | 1985 | 4568 | 0.000 |
Why?
|
Child | 1 | 2005 | 77709 | 0.000 |
Why?
|